Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Broggi G, Barresi V (2023) Assessment of CDKN2A/B homozygous deletion in gliomas: to FISH or not to FISH? J Neuropathol Exp Neurol 82:742–744. https://doi.org/10.1093/jnen/nlad045
Ikeda H, Yamaguchi S, Ishi Y, Wakabayashi K, Shimizu A, Kanno-Okada H, Endo T, Ota M, Okamoto M, Motegi H, Iwasaki N, Fujimura M (2023) Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: a case report. Neuropathology 43:413–420. https://doi.org/10.1111/neup.12902
Komori T (2022) The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles. Brain Tumor Pathol 39:47–50. https://doi.org/10.1007/s10014-022-00428-3
Masui K, Onizuka H, Nitta M, Muragaki Y, Kawamata T, Komori T (2023) Recurrent high-grade astrocytoma with somatic mosaicism of isocitrate dehydrogenase gene mutation. Pathol Int 73:144–146. https://doi.org/10.1111/pin.13308
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. https://doi.org/10.1056/NEJMoa2304194
Nicholson JG, Fine HA (2021) Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 11:575–590. https://doi.org/10.1158/2159-8290.CD-20-1474
Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Narita Y, Ichimura K, Yoshida A (2021) Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34:688–700. https://doi.org/10.1038/s41379-020-00701-w
Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A (2018) Novel, improved grading system (s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4
Umehara T, Arita H, Yoshioka E, Shofuda T, Kanematsu D, Kinoshita M, Kodama Y, Mano M, Kagawa N, Fujimoto Y, Okita Y, Nonaka M, Nakajo K, Uda T, Tsuyuguchi N, Fukai J, Fujita K, Sakamoto D, Mori K, Kishima H, Kanemura Y (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:99. https://doi.org/10.1186/s40478-019-0749-8
Xi S, Huang Q, Zeng J (2024) A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma. J Neuropathol Exp Neurol 83:125–130. https://doi.org/10.1093/jnen/nlad112
Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA (2018) Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. Lab Invest 98:403–413. https://doi.org/10.1038/s41374-017-0007-2
Acknowledgements
The authors thank medical technologists at Tokyo Women’s Medical University for their helpful assistance. KM, HO and TK conducted the neuropathological examinations; YM and TK performed the surgery and compiled the clinical records; KM, AK and TK drafted the manuscript; all the authors reviewed the manuscript.
Funding
This work was supported in part by Grant-in-Aid from Takeda Science Foundation and Japan Society for the Promotion of Science KAKENHI Grant JP23K06487 (KM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Approval of the research protocol
The ethical committees of Tokyo Women’s Medical University (3540-R6).
Animal studies
Not applicable.
Research involving recombinant DNA
Not applicable.
Informed consent
Written informed consent was obtained.
Registry and the registration no. of the study/trial
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Masui, K., Onizuka, H., Muragaki, Y. et al. Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma. Brain Tumor Pathol 41, 92–95 (2024). https://doi.org/10.1007/s10014-024-00484-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-024-00484-x